[HTML][HTML] From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
Translational Research, 2022•Elsevier
While the coronavirus disease 19 (COVID-19) pandemic has transformed the medical and
scientific communites since it was first reported in late 2019, we are only beginning to
understand the chronic health burdens associated with this disease. Although COVID-19 is
a multi-systemic disease, the lungs are the primary source of infection and injury, resulting in
pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS). Given that
pulmonary fibrosis is a well-recognized sequela of ARDS, many have questioned whether …
scientific communites since it was first reported in late 2019, we are only beginning to
understand the chronic health burdens associated with this disease. Although COVID-19 is
a multi-systemic disease, the lungs are the primary source of infection and injury, resulting in
pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS). Given that
pulmonary fibrosis is a well-recognized sequela of ARDS, many have questioned whether …
While the coronavirus disease 19 (COVID-19) pandemic has transformed the medical and scientific communites since it was first reported in late 2019, we are only beginning to understand the chronic health burdens associated with this disease. Although COVID-19 is a multi-systemic disease, the lungs are the primary source of infection and injury, resulting in pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS). Given that pulmonary fibrosis is a well-recognized sequela of ARDS, many have questioned whether COVID-19 survivors will face long-term pulmonary consequences. This review is aimed at integrating our understanding of the pathophysiologic mechanisms underlying fibroproliferative ARDS with our current knowledge of the pulmonary consequences of COVID-19 disease.
Elsevier